Spring brings another good news! Following the European patent allowance for cationic lipids in February 2026, our patent portfolio has achieved another milestone. In April 2026, several cationic lipid products independently developed by Sinopeg—including DHA-1, SNP24-1, SNP25-1, and SNP26-1—successfully received U.S. patent allowance, protected in the form of a Markush formula. With this, the DHA-1 series cationic lipids have now secured patent coverage in the three core markets of China, Europe, and the United States, establishing a global intellectual property moat for this key excipient of LNP delivery systems. Patent Title: Cationic Lipid, Liposome Containing Cationic Lipid, and Nucleic-Acid Pharmaceutical Composition Containing Liposome and Formulation and Application Thereof Patent Application No.: 18/269,728 Applicant: Xiamen Sinopeg Biotech Co., Ltd. Source: Notice of Allowance from the USPTO (screenshot) Patent Breakthrough: Comprehensive Coverage from China to Europe and the U.S. DHA-1, SNP24-1, SNP25-1, SNP26-1, and others are cationic lipids independently developed by Sinopeg. They feature high biocompatibility and high transfection efficiency, effectively bypassing existing patent restrictions and providing a reliable, localized alternative for the LNP delivery field. In terms of IP strategy, the patent journey for the DHA-1 series has been solid and methodical: September 2022: Granted Chinese patent (priority application). October 2023: Granted patent for PCT national phase entry in China. February 2026: Granted European patent, achieving full coverage in China and Europe. April 2026: Granted U.S. patent, protected in Markush formula form. Thus, the DHA-1 series cationic lipids now hold patent protection in all three major markets—China, Europe, and the U.S.—providing a strong legal foundation for compliant commercialization and global business expansion. Beyond patent coverage, DHA-1 also leads in regulatory compliance: it has successfully completed CDE pharmaceutical excipient filing in China (Filing No. F20230000445) and has submitted a U.S. FDA DMF (Filing No. 039452). Customers can directly reference Sinopeg's filed dossiers in both China and the U.S., significantly reducing submission preparation time and accelerating project progress. Markush Formula Allowance: Broader Protection, Stronger Barrier What is a Markush formula allowance, and how is it different from a standard compound patent? Simply put, the Markush formula is one of the most valuable forms of patent protection in the pharmaceutical compound field. It uses a "generic formula" approach, covering a class of compounds that share a common structure and similar properties, rather than protecting only a single structure. For this series of cationic lipids, this means: Broader protection – The patent covers not only the dozens of specific structures exemplified (including DHA-1, SNP24-1, SNP25-1, SNP26-1) but also other cationic lipid structures sharing the same core ...

As we prepare to welcome a season of strength, speed, and success, our team will be taking a short break to celebrate the Chinese New Year with our loved ones. Holiday Notice: We will be closed from February 15 to February 23. Normal business operations will resume on February 24. During this period, if you have any urgent inquiries or project needs, please feel free to: Leave us a message via our website: www.sinopeg.com Or email us at: sales@sinopeg.com We’ll get back to you promptly upon our return. Wishing you and your family a joyful, prosperous, and horse-powered New Year! #ChineseNewYear #YearOfTheHorse #SpringFestival #HolidayNotice #GlobalBusiness #Sinopeg #ClientCare #NewYear2026

Within the intricate system of Radiopharmaceutical Drug Conjugates (RDCs), there exists a component that, while seemingly auxiliary, is critically vital, directly impacting the drug's stability and targeting efficiency. This component is the monodisperse polyethylene glycol (PEG) derivative. Serving as the crucial linker in RDC drugs, it is quietly propelling tumor precision therapy into a new, more controllable and efficient phase. What are RDC Drugs? Structurally, Radiopharmaceutical Drug Conjugates (RDCs) primarily consist of a targeting ligand (Ligand, such as antibodies, peptides, or small molecules), a linker, a chelator, and a radioisotope. Their main mechanism involves using the targeting ligand to deliver the radioisotope to a specific target, leveraging the radiation effects of the radioisotope to achieve precise killing of tumor cells or imaging for medical diagnosis and treatment. (Image Source: WuXi AppTec Marketing Department WeChat Official Account) Globally, the R&D progress of RDC drugs is remarkable. Currently, over 10 RDC drugs have been approved for marketing, with several therapeutic radiopharmaceuticals achieving significant success in areas like neuroendocrine tumors and prostate cancer. These successes mark the formal entry of tumor treatment into a new era of precise targeted therapy. Compared to traditional chemotherapy, RDC drugs can act more precisely on tumor cells, improving treatment efficacy while reducing toxic side effects. Chinese pharmaceutical companies are also accelerating their deployment in this cutting-edge field. According to statistics from the MoShang Medical Database, as of now, over 120 domestic companies and institutions are involved in RDC R&D, demonstrating China's strong momentum in the field of nuclear medicine innovation. As an emerging force in tumor therapy, targeted radiopharmaceuticals stand at the forefront of the era's development, with their immense potential drawing significant attention. They are expected to become the next major breakthrough point in tumor treatment. The Wave of PEG-Modified Radiopharmaceutical R&D To date, numerous studies on PEG-modified peptide radiopharmaceuticals have been reported, and several radiopharmaceuticals in Phase II/III clinical trials have successfully employed PEG modification strategies. In the current wave of RDC R&D, high-quality, stably supplied key excipients are the cornerstone ensuring smooth R&D progress. As a dedicated player in the field of PEG derivatives, Sinopeg relies on its advanced synthesis and purification technology platform to provide a series of monodisperse PEG derivatives with well-defined structures, high purity, and functionalized termini, offering solid support for RDC drug R&D. As RDC drug R&D deepens, the demand for high-quality PEG derivatives will continue to grow. Professional and reliable suppliers will become an important force driving innovation in this field! Sinopeg boasts an extensive i...

Radioconjugate drugs—combining radionuclides with targeting ligands such as antibodies, peptides, or small molecules via chelators and linkers—represent a cutting-edge approach in precision medicine. By delivering radionuclides directly to disease sites, they enable targeted tumor ablation or highly accurate diagnostic imaging, revolutionizing both therapy and diagnostics. To enhance the stability, solubility, and pharmacokinetics of your radioconjugates, Sinopeg offers high-purity, monodisperse polyethylene glycol (PEG) derivatives. These well-defined PEG linkers ensure improved conjugation efficiency, reduced immunogenicity, and optimized in vivo performance—key factors for developing safe and effective radiopharmaceuticals. Whether you are designing novel radioligands or optimizing existing constructs, Sinopeg’s tailored PEG solutions can accelerate your R&D and help bring more precise, impactful treatments to patients. Reach out to explore how we can support your next-generation radioconjugate projects! Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG

J Exp Med. 2025 Sep 1;222(9):e20241454. doi: 10.1084/jem.20241454. Epub 2025 Jun 6. Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control Abstract Conventional mRNA cancer vaccines can expand the quantity of tumor-specific CD8 T cells, but their effector function might be compromised. Specific cytokine signaling may enhance T cell differentiation for better tumor killing. We screened various cytokines and identified IL-12 as a potent adjuvant for mRNA vaccines, though with significant systemic toxicity. To balance efficacy and toxicity, we developed a membrane-tethered IL-12 (mtIL12) adjuvant mRNA vaccine. This design restricts mtIL12 expression to the surface of antigen-presenting cells, thereby selectively activating antigen-specific T cells without affecting bystander T or NK cells. mtIL12 adjuvant mRNA vaccination induced a unique pre-effector T cell subset that gives rise to highly responsive effector T cells, resulting in superior anti-tumor activity. Moreover, this approach overcame immune checkpoint therapy resistance and prevented cancer metastasis. Our study highlights that next-generation mRNA vaccines encoding membrane-tethered cytokine adjuvants can generate potent effector T cells, offering effective tumor control with reduced toxicity. Product: Wholesale Best Excipient For DNA/RNA Delivery,professional Excipient For DNA/RNA Delivery Suppliers

Bioact Mater. 2024 Jun 21:40:430-444. doi: 10.1016/j.bioactmat.2024.06.021. eCollection 2024 Oct. Kneadable dough-type hydrogel transforming from dynamic to rigid network to repair irregular bone defects Abstract Irregular bone defects, characterized by unpredictable size, shape, and depth, pose a major challenge to clinical treatment. Although various bone grafts are available, none can fully meet the repair needs of the defective area. Here, this study fabricates a dough-type hydrogel (DR-Net), in which the first dynamic network is generated by coordination between thiol groups and silver ions, thereby possessing kneadability to adapt to various irregular bone defects. The second rigid covalent network is formed through photocrosslinking, maintaining the osteogenic space under external forces and achieving a better match with the bone regeneration process. In vitro, an irregular alveolar bone defect is established in the fresh porcine mandible, and the dough-type hydrogel exhibits outstanding shape adaptability, perfectly matching the morphology of the bone defect. After photocuring, the storage modulus of the hydrogel increases 8.6 times, from 3.7 kPa (before irradiation) to 32 kPa (after irradiation). Furthermore, this hydrogel enables effective loading of P24 peptide, which potently accelerates bone repair in Sprague-Dawley (SD) rats with critical calvarial defects. Overall, the dough-type hydrogel with kneadability, space-maintaining capability, and osteogenic activity exhibits exceptional potential for clinical translation in treating irregular bone defects. Keywords: Dough-type hydrogel; Dynamic network; Irregular bone defect; Kneadable; Rigid network. Product: Manufacturer Of PEG Derivative By Structure,Wholesale PEG Derivative By Structure

Pharmaceutics. 2025 Jan 24;17(2):157. doi: 10.3390/pharmaceutics17020157. Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge Abstract Background/Objectives: Transforming Growth Factor-beta (TGFβ1) plays a core role in the process of pulmonary fibrosis (PF). The progression of pulmonary fibrosis can be alleviated by siRNA-based inhibiting TGF-β1. However, the limitations of naked siRNA lead to the failure of achieving therapeutic effect. This study aimed to design lipid nanoparticles (LNPs) that can deliver siTGF-β1 to the lungs for therapeutic purposes. Methods: The cytotoxicity and transfection assay in vitro were used to screen ionizable lipids (ILs). Design of Experiments (DOE) was used to obtain novel LNPs that can enhance resistance to atomization shear forces. Meanwhile, the impact of LNPs encapsulating siTGF-β1 (siTGFβ1-LNPs) on PF was investigated. Results: When DLin-DMA-MC3 (MC3) was used as the ILs, the lipid phase ratio was MC3:DSPC:DMG-PEG2000:cholesterol = 50:10:3:37, and N/P = 3.25; the siTGFβ1-LNPs could be stably delivered to the lungs via converting the siTGFβ1-LNPs solution into an aerosol (atomization). In vitro experiments have confirmed that siTGFβ1-LNPs have high safety, high encapsulation, and can promote cellular uptake and endosomal escape. In addition, siTGFβ1-LNPs significantly reduced inflammatory infiltration and attenuated deposition of extracellular matrix (ECM) and protected the lung tissue from the toxicity of bleomycin (BLM) without causing systemic toxicity. Conclusions: The siTGFβ1-LNPs can be effectively delivered to the lungs, resulting in the silencing of TGF-β1 mRNA and the inhibition of the epithelial-mesenchymal transition pathway, thereby delaying the process of PF, which provides a new method for the treatment and intervention of PF. Keywords: design of experiments (DOE); lipid nanoparticles (LNPs); pulmonary fibrosis (PF); siRNA delivery; transforming growth factor β1 (TGF-β1). Product: Wholesale Best Excipient For DNA/RNA Delivery,professional Excipient For DNA/RNA Delivery Suppliers